Autophagy inhibition [54], spleen tyrosine kinase (SYK) [55], and IGF2BP1 [56] are potential future therapeutic targets for ETV6::RUNX1-driven B-cell precursor acute lymphoblastic leukemia due to their roles in ETV6::RUNX1 cell survival and prognosis. This evidence concerns the gene IGF2BP1 and precursor B-cell acute lymphoblastic leukemia.